VRNA vs. CRNX, AXSM, MRUS, HCM, CORT, RARE, PBH, BHVN, XENE, and FOLD
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Merus (MRUS), HUTCHMED (HCM), Corcept Therapeutics (CORT), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), Biohaven (BHVN), Xenon Pharmaceuticals (XENE), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Verona Pharma (NASDAQ:VRNA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, community ranking, media sentiment, institutional ownership and valuation.
Verona Pharma currently has a consensus price target of $33.20, indicating a potential upside of 175.06%. Crinetics Pharmaceuticals has a consensus price target of $60.92, indicating a potential upside of 37.17%. Given Verona Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Crinetics Pharmaceuticals.
In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Verona Pharma. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 4 mentions for Verona Pharma. Crinetics Pharmaceuticals' average media sentiment score of 0.74 beat Verona Pharma's score of 0.49 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Verona Pharma has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Verona Pharma's return on equity of -25.09% beat Crinetics Pharmaceuticals' return on equity.
Verona Pharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Verona Pharma received 169 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. Likewise, 79.95% of users gave Verona Pharma an outperform vote while only 67.30% of users gave Crinetics Pharmaceuticals an outperform vote.
Verona Pharma has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Verona Pharma is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Verona Pharma beats Crinetics Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
